The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.
Abstract
Non-Hodgkin's lymphoma (NHL) is a malignancy that occurs frequently in the elderly with a median age greater than 60 years. However, most chemotherapy trials have included predominantly patients less than 60 years of age. We treated 157 patients with diffuse aggressive NHL between September 1982 and May 1986 with cyclophosphamide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), procarbazine, bleomycin, vincristine, and prednisone (CAP/BOP). There were no treatment exclusions for age. Patients in this study ranged in age from 15 to 91 years (median, 63) with 112 patients greater than or equal to 60 years of age. The overall complete remission (CR) rate was 65% with no significant difference for age less than 60 (76%) v age greater than or equal to 60 (61%) (P = .18). With a median 36-month follow-up (range, 22 to 65 months), the overall 5-year survival was 42%. The patients less than 60 years old had a 62% 5-year survival in contrast to a 34% 5-year survival in those patients greater than or equal to age 60 (P = .01). The deaths attributed to tumor or treatment-related toxicity were similar above and below age 60. The difference in survival was due to other causes of death not obviously related to the lymphoma or its therapy-occurring in 22% of patients greater than or equal to 60 years of age but only 2% of patients less than 60 years (P = .005). Our data supports the position that aggressive NHL in elderly patients is not significantly less responsive than in younger patients; however, the inclusion of older patients in clinical trials will decrease the overall survival secondary to deaths due to apparently unrelated causes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Committee on Hodgkin's Disease Staging Classification.
Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., & Tubiana, M. (1971) · PubMed · Cited by 4,166
CALCULATION OF SURVIVAL RATES FOR CANCER
Berkson, J., & Gage, R. P. (1950) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(26)04443-5 · Cited by 940
MACOP-B Chemotherapy for the Treatment of Diffuse Large-Cell Lymphoma
KLIMO, P., & CONNORS, J. M. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-5-596 · Cited by 664
Dixon, D. O., Neilan, B., Jones, S. E., Lipschitz, D. A., Miller, T. P., Grozea, P. N., & Wilson, H. E. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.3.295 · Cited by 360
Skarin, A. T., Canellos, G. P., Rosenthal, D. S., Case, D. C., MacIntyre, J. M., Pinkus, G. S., Moloney, W. C., & Frei, E. (1983) · Journal of Clinical Oncology · doi:10.1200/jco.1983.1.2.91 · Cited by 334
ARMITAGE, J. O., & POTTER, J. F. (1984) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1984.tb02020.x · Cited by 230
Self-citationCb, B., Jl, C., & Ellerton, J. A. (1980) · PubMed · Cited by 110
Cancer: special considerations in older patients.
Sw, H. (1984) · PubMed · Cited by 8
Cited by
Armitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Self-citationShankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
Self-citationTreatment of Non-Hodgkin's Lymphoma
Wood, A. J. J., & Armitage, J. O. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281409 · Cited by 376
Self-citationSonneveld, P., de Ridder, M., van der Lelie, H., Nieuwenhuis, K., Schouten, H., Mulder, A., van Reijswoud, I., Hop, W., & Lowenberg, B. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2530 · Cited by 280
Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high- risk" disease?
Shipp, M. (1994) · Blood · doi:10.1182/blood.v83.5.1165.1165 · Cited by 278
Metadata
- Authors
- Vose, J. M., Armitage, J. O., Weisenburger, D. D., Bierman, P. J., Sorensen, S., Hutchins, M., Moravec, D. F., Howe, D., Dowling, M. D., & Mailliard, J.
- Venue
- Journal of Clinical Oncology
- Published
- 1988-12
- Volume
- 6
- Issue
- 12
- Pages
- 1838-1844
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2174428418
- Cited by
- 272
- References
- 8
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. https://app.cochat.ai/papers/10.1200/jco.1988.6.12.1838
- The paper
- Vose, J. M., Armitage, J. O., Weisenburger, D. D., Bierman, P. J., Sorensen, S., Hutchins, M., Moravec, D. F., Howe, D., Dowling, M. D., & Mailliard, J. (1988). The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1988.6.12.1838
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.